Drugs / ASP2957
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07052929 | Dec 2025 → Oct 2027 expected | X-linked myotubular myopathy | Astellas Gene Therapies | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2957 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07052929 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT07052929 ↗ |
| Target | MTM1 | “Researchers have developed ASP2957 to get a healthy MTM1 gene into the body.” NCT07052929 ↗ |